GABA
CAS 56-12-2
Purity≥99.0%
GABA powder for capsule, powder and beverage formulation development
Gamma-Aminobutyric Acid Powder (CAS 56-12-2), specification ≥99.0%. Crystalline gamma-aminobutyric acid in 25 kg bulk packs, with assay and testing information in the specifications section. Batch COA and evaluation samples are available. MOQ: 25 kg. nutrition & functional ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | GABA powder for capsule, powder and beverage formulation development |
| Application Scenarios | formulation development |
| CAS Number | 56-12-2 |
| Purity | ≥99.0% |
| Molecular Formula | C₄H₉NO₂ |
| Molecular Weight | 103.12 g/mol |
| Appearance | White crystalline powder |
| Solubility | Freely soluble in water |
| Storage | Room temperature, dry |
| Shelf Life | 36 months |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
Gamma-aminobutyric acid (GABA; CAS 56-12-2) is a non-protein amino acid with formula C4H9NO2 and formula weight 103.12 g/mol. The supplied material is a crystalline bulk powder. The current product specification lists assay at ≥99% by HPLC; review the lot-specific COA for actual results, including appearance, assay, pH, loss on drying, ash and chloride. Grade, intended use and destination-market requirements should be confirmed for each order.
GABA Bulk Supply
PathGene supplies GABA, CAS 56-12-2, with specification ≥99.0%.
25 kg Crystalline GABA Packaging
Crystalline GABA with 25 kg bulk packaging for formulation projects.
Batch Quality Documentation
Batch COA supports the quality evaluation of GABA and the agreed purchasing specification.
Evaluation Samples
Request GABA samples for incoming-quality evaluation and project trials.
Supply and Packaging
MOQ: 25 kg. Packaging options: 25 kg.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PGGABA-260616
Test date
2026-06-17
Specification
In-house
Pack size
25 kg/drum
Storage
Room temperature, dry
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White to pale yellow crystals | White crystals |
| Assay | ≥99% | 99.6% |
| pH | 6.5–7.5 | 7.2 |
| Loss on drying | ≤1.0% | 0.04% |
| Ash content | ≤0.1% | 0.01% |
| Chloride | ≤0.02% | Conforms |
Request a reviewed COA through the quality documents section and confirm its product form and batch.
Hard capsules
Powders
Softgels
Tablets
Sublingual tablets
Oral dissolving films
Powders
Sachets
Oral liquids
Qualify GABA and theanine separately; animal combination studies do not establish human intake.
99.6%
Assay
0.01%
Ash content
PGGABA-260616 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Study combinations, individual-ingredient mechanisms and product precedents are distinguished; expand each entry for scope and pilot-development checks.
A 2019 animal sleep-model study evaluated GABA with L-theanine, supporting a combination research direction rather than human dosing or finished-product efficacy. Test dry-blend uniformity, reconstitution flavour and stored assays separately.
Expand research and formulation notes +Collapse research and formulation notes −Development rationale: A 2019 animal sleep-model study evaluated GABA with L-theanine, supporting a combination research direction rather than human dosing or finished-product efficacy. Test dry-blend uniformity, reconstitution flavour and stored assays separately.
Evidence scope: A 2019 animal sleep-model study evaluated GABA with L-theanine, supporting a combination research direction rather than human dosing or finished-product efficacy. Test dry-blend uniformity, reconstitution flavour and stored assays separately.
Pilot checks: Retain individual-ingredient, blend and carrier controls; check uniformity and post-process assays before packaged samples, documenting study formulations separately from new candidates.
View original research or document ↗Both are used in relaxation, stress and sleep formulation research; screen as a neurotransmitter and stress-management concept while monitoring additive sedation and human dosing.
Expand research and formulation notes +Collapse research and formulation notes −Development rationale: Both are used in relaxation, stress and sleep formulation research; screen as a neurotransmitter and stress-management concept while monitoring additive sedation and human dosing.
Evidence scope: Mechanism and formulation direction; human evidence for oral GABA remains limited.
Pilot checks: Retain individual-ingredient, blend and carrier controls; check uniformity and post-process assays before packaged samples, documenting study formulations separately from new candidates.
View original research or document ↗Literature-Supported Research Directions
GABA is a major inhibitory neurotransmitter in the central nervous system. Research focuses on neural-excitability balance, stress responses and sleep-related signaling. Human evidence for oral GABA remains limited and mixed, so this is best presented as a formulation and mechanism research direction.
Citation: Hepsomali et al., Frontiers in Neuroscience (2020), systematic review of oral GABA for stress and sleep.View source
GABA can support research into GABAergic signaling, relaxation, sleep quality and stress adaptation. Finished-product outcomes depend on dose, absorption, individual variation and the formulation matrix and require human validation.
Citation: Hepsomali et al. (2020): placebo-controlled trials showed limited evidence for stress and very limited evidence for sleep.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
25 kg
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Because GABA lacks a strong native UV chromophore, purity is typically confirmed by HPLC with pre-column derivatization (e.g., OPA or dansyl chloride) or by pharmacopeia-style non-aqueous acid-base titration, either of which is suitable for routine batch release testing. Buyers should confirm the exact assay method, reference standard, and column/derivatization conditions used on the Certificate of Analysis, and are welcome to request the full CoA or submit samples for independent third-party verification before large orders.
GABA is freely soluble in water, readily forming clear solutions at typical use levels (roughly 1-10% w/v) suitable for functional beverages, effervescent tablets, and liquid formulations. For solid dosage forms, the crystalline powder blends well directly into tablets, capsules, sachets, and granulated powders. Because GABA is an amino acid, it may undergo Maillard browning reactions with reducing sugars under heat or prolonged storage, so formulators are advised to run compatibility, stability, and shelf-life testing under their specific process conditions (pH, temperature, co-ingredients) before finalizing a formulation.
PathGene supplies gamma-aminobutyric acid (GABA) powder, CAS 56-12-2, with an HPLC assay specification of ≥99.0%. Each lot’s measured assay is recorded in its matching COA.
GABA batch quality information includes appearance, assay, pH, loss on drying, ash and chloride. Apply the complete agreed specification for acceptance and verify the results against the COA matching the offered lot.
Verify GABA source and manufacturing route through product-specific source declarations and process documentation. A batch COA records identity and quality-test results. Include any required source or process restrictions separately in supplier-qualification requirements.
Qualify GABA against the quality standard, source documentation and market requirements for its intended use. This product uses an in-house raw-material specification with an HPLC assay of ≥99.0%. Food or pharmaceutical projects also require the corresponding grade documentation and applicable requirements.
The raw-material MOQ for GABA powder is 25 kg, with pack options of 25 kg. Typical lead time is 3–5 business days, with dispatch confirmed for the order.
Samples are available for evaluation. Confirm sample size, any applicable fee, shipping terms and accompanying documents with the sales team.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Technical Resources
Related Products
Citicoline (CDP-Choline) Powder
Glutathione (Reduced) Powder
Calcium L-5-Methyltetrahydrofolate Powder
Interested in GABA?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
